Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013

Hemoglobin

Volumn 38, Issue 2, 2014, Pages 115-118

  Kosaryan, Mehrnoush ^a   Karami, Hossein ^a   Zafari, Mandana ^a   Yaghobi, Negar ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Compliance; Hemoglobin (Hb); Hydroxyurea (HU); Iran; Non transfusion dependent thalassemia major ( TM); Treatment; Globin gene mutation

Indexed keywords

HEMOGLOBIN; HYDROXYUREA; ANTISICKLING AGENT; HEMOGLOBIN BETA CHAIN;

ADULT; BLOOD CELL COUNT; BLOOD TRANSFUSION; CREATININE BLOOD LEVEL; ELECTROPHORESIS; ERYTHROCYTE CONCENTRATE; FEMALE; GENE MUTATION; HUMAN; IRAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SIDE EFFECT; THALASSEMIA MAJOR; TREATMENT DURATION; BETA-THALASSEMIA; GENETICS; HEMATOCRIT; MEAN CORPUSCULAR VOLUME; MUTATION; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTISICKLING AGENTS; BETA-GLOBINS; BETA-THALASSEMIA; BLOOD CELL COUNT; BLOOD TRANSFUSION; ERYTHROCYTE INDICES; FEMALE; HEMATOCRIT; HUMANS; HYDROXYUREA; IRAN; MALE; MUTATION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896278172     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2013.869229     Document Type: Review

References (29)

1. Ley TJ, Desimon J, Anagnou NP, et al. 5-Azacytidine selectively increases g-globin synthesis in a patient with b thalassemia. N Engl J Med. 1982;307(24):1469-1475.
2. Yavarian M, Karimi M, Bakker E, et al. Response to hydroxyurea treatment in Iranian transfusion-dependent b-thalassemia patients. Haematologica. 2004;89(10):1172-1178.
3. Musallam K, Taher A, Cappellini M, Sankaran V. Clinical experience with fetal hemoglobin induction therapy in patients with b-thalassemia. Blood. 2013;121(12):2199-2212.
4. Hajjah FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125(3):490-492.
5. Olivieri N. Reactivation of fetal hemoglobin in patients with b-thalassemia. Semin Hematol. 1996;33(1):24-42.
6. Olivieri N, Rees D, Ginder G, et al. Treatment of thalassemia major with phenylbutyrate and hydroxyurea. Lancet. 1997; 350(9076):491-492.
7. Arruda VR, Lima CS, Saad ST, Costa FF. Successful use of hydroxyurea in b-thalassemia major. N Eng J Med. 1997; 336(13):964.
8. Saxon B, Rees D, Olivieri N. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in b thalassaemia. Br J Haematol. 1998;101(3):416-419.
9. Kosaryan M, Yoosefy G, Mahdavi M, et al. The effect of hydroxyurea in milder forms of thalassemia. J Mazandaran Univ Med Sci. 2000;9(25):30-38.
10. Tamaddoni A, Toobaii H, Javaheri A. Determination of effectiveness of hydroxyurea in intermedia thalassemia. Proceedings of the 7th International Conference in Thalassemia and Hemoglobinopathies, Bankok, Thailand, June 1999 (Abstract 367).
11. Kosaryan M, Vahidshahi K, Karami H, Ehteshami S. The effect of hydroxyurea in thalassemia major and intermedia in Iranian patients. Pakistan J Med Sci. 2009;25(1):74-78.
12. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005; 27(7):380-385.
13. Karimi M, Borzouee M, Mehrabani A, Cohan N. Echocardiographic finding in b-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in b-thalassemia intermedia. Eur J Haematol. 2009; 82(3):213-218.
14. Karimi M. Hydroxyurea in the management of thalassemia intermedia. Proceedings of the 1st Pan-Middle Eastern Conference on Haemoglobinopathies, Damascus, Syria, 1-2 May 2009. Hemoglobin. 2009;33(Suppl 1):S177-S182.
15. Karimi M, Cohan N, Moosavizadeh K, et al. Adverse effects of hydroxyurea in b-thalassemia intermedia patients: 10 years' experience. Pediatr Hematol Oncol. 2010;27(3):205-211.
16. Hashemisoteh M, Akhavan-Niaki H, Kosaryan M, et al. The role of b gene mutations in response to hydroxyurea therapy in patients with b thalassemia patients. J Mazandaran Univ Med Sci. 2008; 18(64):1-10.
17. www.FDA.gov.
18. Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in b thalassemia. Am J Hematol. 2008;83(5):366-370.
19. Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007; 47(10):1830-1836.
20. Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotypephenotype relationship of patients with b-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012; 95(1):51-56.
21. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005; 27(7):380-385.
22. Kosaryan M, Mojtahedzadeh F, Akhavan-Niaki H. The relationship of Xmn1 genotype with response to hydroxyurea in b thalassemia. Proceedings of the 9th International Conference in Thalassemia and Hemoglobinopathies held in Palermo, Italy, October 15-19 2003 (Poster 7).
23. Ehsani M, Hedayati-Asl A, Bagheri A, et al. Hydroxyurea induced hematological response in transfusion-independent b-thalassemia intermedia: case series and review of literature. Pediatr Hematol Oncol. 2009;26(8):560-565.
24. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major b-thalassemia and importance of genetic screening. Ann Hematol. 2004; 83(7):430-433.
25. Karami H, Vahidshahi K, Kosaryan M, et al. Relationship between use of hydroxyurea and cholelithiasis in patients with major and intermediate b-thalassemia. J Mazandaran Univ Med Sci. 2007; 17(61):62-68 [abstract in English].
26. Mojtahedzadeh F, Kosaryan M, Kowsarian S, Karami H. Effect of hydroxyurea on extramedullary hematopoiesis masses in patients with b thalassemia intermedia. J Pejohandeh (Med J Shahid Beheshti Univ). 2008;13(2):81-88.
27. Rashidy-Ghader F, Kosaryan M. Cardiologic evaluation of thalassemic patients while using hydroxyurea. J Mazandaran Univ Med Sci. 2006;16(51):37-42 [abstract in English].
28. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317-1322.
29. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Int Med. 2008;148(12):939-956.